Rapport Therapeutics, Inc. (RAPP) on GreekSoup https://greeksoup.ai/stocks/us/rapp/ Every dated entry in the public record on Rapport Therapeutics, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Fri, 30 Oct 2026 00:00:00 +0000 Rapport Therapeutics, Inc.: Sanchez Ramiro (Director) bought 3,600 shares at $27.35 on 23 October 2026, $98,478https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-23:34747ff045Fri, 23 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 2,210 shares (under a trading plan set in advance) at $29.16 on 21 October 2026, $64,448https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-23:5181c3137fFri, 23 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Silva Paul M (Director), by Paul M Silva 2016 Declaration of Trust U/A DTD 12/19/2016, bought 3,680 shares at $27.07 on 22 October 2026, $99,636https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-22:ba3b1b7c65Thu, 22 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Young Wendy B. (Director) bought 3,789 shares at $26.39 on 22 October 2026, $99,992https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-22:77bbc9f37aThu, 22 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Paul Steven M (Director), by Paul Capital Strategy III Fund LLC, bought 35,714 shares at $27.28 on 22 October 2026, $974,278https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-22:2dcb4c46a3Thu, 22 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Maraganore John (Director), by John M. Maraganore Revocable Trust, bought 8,239 shares at $26.38 on 22 October 2026, $217,344https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-22:026d5b6af2Thu, 22 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Maraganore John (Director), by John M. Maraganore Revocable Trust, bought 1,172 shares at $26.92 on 22 October 2026, $31,547https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-22:c488c56f45Thu, 22 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ignelzi Troy A. (Chief Financial Officer) bought 5,500 shares at $26.10 on 21 October 2026, $143,550https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-21:d091b3032cWed, 21 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc. filed 8-K: regulation fd disclosure, other eventshttps://greeksoup.ai/stocks/us/rapp/filings/us:RAPP:filing:2026-10-20:51795040c3Tue, 20 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: short interest 3,051,500 shares at the 15 October 2026 settlement, 11.76 days to coverhttps://greeksoup.ai/stocks/us/rapp/short-interest/us:RAPP:short-interest:2026-10-15:034c12728aThu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 1,147 shares (under a trading plan set in advance) at $30.66 on 7 October 2026, $35,167https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-08:be7d97f725Thu, 08 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 3,375 shares (under a trading plan set in advance) at $32.03 on 6 October 2026, $108,106https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-08:72f0cd7401Thu, 08 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Form 144, Abraham N. Ceesay plans to sell 39,470 shares worth $1.2 million around 6 October 2026https://greeksoup.ai/stocks/us/rapp/planned-sales/us:RAPP:planned-sale:2026-10-06:deb97d4020Tue, 06 Oct 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Gault Cheryl (Chief Operating Officer) sold 7,925 shares (under a trading plan set in advance) at $33.04 on 30 September 2026, $261,813https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-01:499241da9cThu, 01 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Gault Cheryl (Chief Operating Officer) sold 2,075 shares (under a trading plan set in advance) at $33.76 on 30 September 2026, $70,043https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-10-01:b7b63d030aThu, 01 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Form 144, CHERYL GAULT plans to sell 10,000 shares worth $330,200 around 30 September 2026https://greeksoup.ai/stocks/us/rapp/planned-sales/us:RAPP:planned-sale:2026-09-30:af4e5bd283Wed, 30 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: short interest 3,194,008 shares at the 30 September 2026 settlement, 4.84 days to coverhttps://greeksoup.ai/stocks/us/rapp/short-interest/us:RAPP:short-interest:2026-09-30:39a758d37aWed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 1,952 shares (under a trading plan set in advance) at $39.05 on 23 September 2026, $76,230https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-09-24:29c6b2184cThu, 24 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 215 shares (under a trading plan set in advance) at $39.86 on 23 September 2026, $8,570https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-09-24:74e21401e0Thu, 24 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 43 shares (under a trading plan set in advance) at $41.05 on 23 September 2026, $1,765https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-09-24:72a3f55262Thu, 24 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: short interest 2,248,069 shares at the 15 September 2026 settlement, 7.91 days to coverhttps://greeksoup.ai/stocks/us/rapp/short-interest/us:RAPP:short-interest:2026-09-15:7cbdc4d25aTue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 7,141 shares (under a trading plan set in advance) at $45.55 on 8 September 2026, $325,308https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-09-09:fe3f8665c4Wed, 09 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 1,069 shares (under a trading plan set in advance) at $46.01 on 8 September 2026, $49,190https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-09-09:db965b4652Wed, 09 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: short interest 2,233,723 shares at the 31 August 2026 settlement, 8.23 days to coverhttps://greeksoup.ai/stocks/us/rapp/short-interest/us:RAPP:short-interest:2026-08-31:38e242e420Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 18,921 shares (under a trading plan set in advance) at $49.57 on 25 August 2026, $937,957https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-08-26:08e8b2f382Wed, 26 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Yeleswaram Krishnaswamy (Chief Development Officer) sold 20,799 shares (under a trading plan set in advance) at $50.31 on 25 August 2026, $1.0 millionhttps://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-08-26:e6dcea41dbWed, 26 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Yeleswaram Krishnaswamy (Chief Development Officer) sold 16,201 shares (under a trading plan set in advance) at $51.06 on 25 August 2026, $827,184https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-08-26:e5208ab16eWed, 26 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Yeleswaram Krishnaswamy (Chief Development Officer) sold 13,160 shares (under a trading plan set in advance) at $50.00 on 24 August 2026, $657,978https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-08-26:ee2390d2caWed, 26 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Form 144, KRISHNASWAMY YELESWARAM plans to sell 37,000 shares worth $1.8 million around 25 August 2026https://greeksoup.ai/stocks/us/rapp/planned-sales/us:RAPP:planned-sale:2026-08-25:734cd4e46cTue, 25 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Form 144, KRISHNASWAMY YELESWARAM plans to sell 11,472 shares worth $553,409 around 24 August 2026https://greeksoup.ai/stocks/us/rapp/planned-sales/us:RAPP:planned-sale:2026-08-24:2c39d63deeMon, 24 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Yeleswaram Krishnaswamy (Chief Development Officer) sold 404 shares (under a trading plan set in advance) at $49.90 on 19 August 2026, $20,160https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-08-20:a35ab0cd28Thu, 20 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Form 144, KRISHNASWAMY YELESWARAM plans to sell 2,092 shares worth $102,529 around 19 August 2026https://greeksoup.ai/stocks/us/rapp/planned-sales/us:RAPP:planned-sale:2026-08-19:711cb3f59eWed, 19 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Schedule 13G/A filed by Third Rock Ventures V, L.P., 13.1% of the classhttps://greeksoup.ai/stocks/us/rapp/holders/us:RAPP:schedule-13:2026-08-14:2c236f94f5Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Schedule 13G/A filed by Cormorant Asset Management, LP, 5.6% of the classhttps://greeksoup.ai/stocks/us/rapp/holders/us:RAPP:schedule-13:2026-08-14:212bf0be6fFri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: short interest 2,225,618 shares at the 14 August 2026 settlement, 7.53 days to coverhttps://greeksoup.ai/stocks/us/rapp/short-interest/us:RAPP:short-interest:2026-08-14:b8a65443ffFri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Schedule 13G/A filed by Capital International Investors, 6.1% of the classhttps://greeksoup.ai/stocks/us/rapp/holders/us:RAPP:schedule-13:2026-08-12:6364d6ae60Wed, 12 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 3,664 shares (under a trading plan set in advance) at $46.90 on 11 August 2026, $171,837https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-08-12:da2ae9def0Wed, 12 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 19,500 shares (under a trading plan set in advance) at $48.04 on 11 August 2026, $936,846https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-08-12:a382e91db3Wed, 12 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 5,794 shares (under a trading plan set in advance) at $48.62 on 11 August 2026, $281,721https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-08-12:b71bf0422cWed, 12 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 14,171 shares (under a trading plan set in advance) at $45.97 on 10 August 2026, $651,492https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-08-12:f855e2ecf4Wed, 12 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc.: Ceesay Abraham (Chief Executive Officer) sold 8,370 shares (under a trading plan set in advance) at $46.75 on 10 August 2026, $391,280https://greeksoup.ai/stocks/us/rapp/insiders/us:RAPP:insider:2026-08-12:0a7430bf8fWed, 12 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc. Q2 FY2025 results: revenue $0, net income -$27 millionhttps://greeksoup.ai/stocks/us/rapp/results/fy2025-q2/us:RAPP:result:2026-08-05:088db87d96Wed, 05 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc. Q2 FY2026 results: revenue $0, net income -$57 millionhttps://greeksoup.ai/stocks/us/rapp/results/fy2026-q2/us:RAPP:result:2026-08-05:581beb447bWed, 05 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/rapp/filings/us:RAPP:filing:2026-08-05:2cd71cc3eeWed, 05 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Rapport Therapeutics, Inc. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/rapp/filings/us:RAPP:filing:2026-08-05:9619623e59Wed, 05 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]>